Company Quick10K Filing
Reva Medical
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 53 $-0
10-Q 2018-11-06 Quarter: 2018-09-30
10-Q 2018-08-07 Quarter: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-K 2018-03-07 Annual: 2017-12-31
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-09 Quarter: 2017-03-31
10-K 2017-02-28 Annual: 2016-12-31
10-Q 2016-11-09 Quarter: 2016-09-30
10-Q 2016-08-09 Quarter: 2016-06-30
10-Q 2016-05-09 Quarter: 2016-03-31
10-K 2016-03-10 Annual: 2015-12-31
10-Q 2015-11-09 Quarter: 2015-09-30
10-Q 2015-08-10 Quarter: 2015-06-30
10-Q 2015-05-14 Quarter: 2015-03-31
10-K 2015-03-30 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-08-07 Quarter: 2014-06-30
10-Q 2014-05-08 Quarter: 2014-03-31
10-K 2014-03-17 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-02-27 Annual: 2012-12-31
10-Q 2012-11-08 Quarter: 2012-09-30
10-Q 2012-08-09 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-Q 2011-11-14 Quarter: 2011-09-30
10-Q 2011-08-15 Quarter: 2011-06-30
10-Q 2011-05-16 Quarter: 2011-03-31
10-K 2011-03-30 Annual: 2010-12-31
8-K 2020-01-14 Enter Agreement, Bankruptcy, Exhibits
8-K 2019-12-13 Other Events, Exhibits
8-K 2019-08-06 Enter Agreement, Off-BS Arrangement, Other Events, Exhibits
8-K 2019-04-02 Enter Agreement, Off-BS Arrangement, Other Events, Exhibits
8-K 2019-03-29 Officers, Other Events, Exhibits
8-K 2019-03-12 Other Events, Exhibits
8-K 2019-03-05 Other Events, Exhibits
8-K 2019-02-25 Other Events, Exhibits
8-K 2019-02-19 Other Events, Exhibits
8-K 2019-02-17 Other Events, Exhibits
8-K 2019-02-04 Exit Costs, Exhibits
8-K 2019-01-14 Officers, Exhibits
8-K 2019-01-02 Officers, Exhibits
8-K 2018-11-14 Regulation FD, Exhibits
8-K 2018-11-05 Officers
8-K 2018-11-05 Earnings, Exhibits
8-K 2018-09-22 Regulation FD, Exhibits
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-07-30 Earnings, Exhibits
8-K 2018-07-30 Enter Agreement, Exhibits
8-K 2018-07-25 Other Events, Exhibits
8-K 2018-06-26 Regulation FD, Exhibits
8-K 2018-05-23 Regulation FD, Exhibits
8-K 2018-05-23 Regulation FD, Exhibits
8-K 2018-05-16 Shareholder Vote
8-K 2018-05-16 Regulation FD, Exhibits
8-K 2018-03-22 Officers
8-K 2018-03-13 Regulation FD, Exhibits
8-K 2018-03-07 Earnings, Exhibits
8-K 2018-02-28 Earnings, Regulation FD, Exhibits
8-K 2018-02-05 Officers, Exhibits
8-K 2018-01-08 Regulation FD, Exhibits

Reva Medical Financials

RVA Metrics, Comps, Filings

Annual | Quarterly

Business

We are a medical device company focused on the development and commercialization of polymer-based bioresorbable products for vascular applications. On April 3, 2017, our second generation and first commercial product, Fantom, was approved for sale under a CE Mark, which allows us to commercialize in Europe and other jurisdictions that recognize the CE Mark. Fantom is a sirolimus-eluting bioresorbable scaffold designed specifically for coronary vascular applications. We believe Fantom is uniquely positioned to meet a market opportunity because of its distinctive features. Fantom is the only bioresorbable scaffold made from Tyrocore™, our proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently x-ray visible, making Fantom the first and only bioresorbable scaffold that is fully visible under x-ray. Fantom is designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation and no requirement for refrigerated storage.

In February 2018, we received CE approval for our third generation product, Fantom Encore, in the 2.5 millimeter diameter size. Fantom Encore has thinner struts than Fantom (95 microns versus 125 microns in the 2.5 millimeter diameter size) and comparable strength and visibility. Fantom Encore has the thinnest struts of any commercially available bioresorbable scaffold. We believe that thin struts are associated with better healing and clinical outcomes. Reductions in strut thickness are considered one of the most important improvements for bioresorbable scaffolds.

We began our commercial launch of Fantom late in the second quarter of 2017 and shipped our first product in the third quarter of 2017. Our sales strategy involves a phased approach beginning first with direct sales in Germany, Switzerland and Austria. We will expand geographically as we move into additional phases of our launch throughout 2018 and beyond. We anticipate commercializing Fantom Encore later in 2018. We expect that the Fantom Encore family will ultimately replace the Fantom family.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Securetech Innovations (SCTF) 3.0 -33% 171 0 0 0 -57 -57 -171
Hospitality Investors Trust (HIT) -2% -96.3 -5% 2,346,467 1,669,804 608,532 -14,913 -120,965 -15,187 1,463,036
Red Metal Resources (RMES) 0.5 -13% 796 1,194 0 0 -106 -66 -32
Heritage Nola Bancorp (HRGG) 0% 8.5 0% 122,340 98,467 193 0 275 1,785 15,230
Stemcell Holdings (STMM) 113% -1.0 26% 12,033 6,023 7,314 8,235 3,099 4,927 -5,116
Liberty Expedia (LEXE) 0% 0.0 -0% 34,646,000 17,341,000 11,536,000 0 -148,000 1,505,000 8,000
Mission Broadcasting (MBCC) 0% 21.5 -3% 216,254 242,843 112,316 0 -6,859 9,999 214,875
Security Land & Development (SLDV) 0% -0.0 53% 24,677 5,836 1,693 0 13,184 19,430 -863
Apache Offshore Investment Partnership (AOIP) 99% -9.8 3% 9,393 1,829 1,412 1,396 250 533 -5,208
Swedish Export Credit (SEK) 0% 302,033,000 283,794,000 0 0 0 0 -0
Teucrium Commodity Trust (TCT) 0% -18.3 5% 209,931 11,900 13,103 0 10,943 10,943 -200,344
Davey Tree Expert (DAVEY) 9% 1.7 6% 570,149 398,166 1,094,814 98,215 32,144 96,951 160,637
TGS (TGSL) 21% 0.2 -37% 3,906 2,483 668 143 -1,429 -1,383 -299
Endra Life Sciences (NDRAU) 0.2 -320% 3,191 1,366 0 0 -10,197 -10,120 -2,268
Vantage Drilling (VDI) 0% 0.4 26% 1,766,407 1,288,261 778,561 0 464,602 631,786 221,791
Ingles Markets (IMKT) 25% 3.0 4% 1,839,033 1,193,628 4,185,631 1,032,601 79,102 275,548 836,159
Po Yuen Cultural (POYE) 0.0 -1,973% 1 68 0 0 -20 -20 -0
CNH Industrial Capital (CNHC) 0% 7.4 1% 12,948,850 11,625,765 877,023 0 149,409 771,476 5,714,322
Eco Energy Tech Asia (EETA) 0.3 -295% 94 3,544 0 0 -278 -278 -94
Wilson Bank Holding (WBHC) -2.1 1% 2,707,053 2,388,865 0 0 35,611 65,827 -141,376

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash59,16138,87619,22925,81416,8956,67420,000
Accounts Receivable63
Inventory627
PP&E1,9602,8217,8572,9202,7192,2771,492
Assets67,32047,39724,78530,19520,0719,48322,661
Accounts Payable1,2846561,4006511,054778756
Long-Term Debt37,78075,36591,655
Liabilities2,7372,7713,96056,644100,63599,076115,474
Stockholders' Equity64,58344,62620,825-26,449-80,564-89,593-92,813
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue45
Cost of Revenue42
Gross Profit3
R&D13,40115,82219,21214,31816,76018,17112,760
SG&A7,6958,0438,7317,6457,2108,6098,572
Tax000
Net Income-20,908-23,776-27,922-51,037-82,594-54,0987,134
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-16,876-18,562-21,943-17,930-19,082-21,259-18,858
Cash Investing-6,165-2,0452,265-44138-729-1,856
Cash Financing4553223124,55910,02511,76732,584